- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03151772
Bioavailability of Disulfiram and Metformin in Glioblastomas (INSIDE)
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
Neuro-oncological trials may fail due to the drug never getting to the intended target (i.e. within the tumor micro environment). Also, changes' occurring in tumor cells when removed from patients and grown in-vitro is another limiting factor influencing the clinical success.
Important questions are therefore:
- Does the drug get there?
- Does the drug do what it is intended to do?
To improve chances of clinical success there is a need for rational and intelligent selection of potential drugs in future trials. This is an initiative for analyzing tumor concentration of preoperative administered repurposed drugs
Study Overview
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Göteborg, Sweden
- Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The subjects must fulfill all the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- A suspected glioblastoma (based on MRI) or recurrent glioblastoma undergoing surgical resection.
- Elective surgical indication
- Age 18 years or older.
- Karnofsky performance status of 60 - 100 (see attachment 3).
- Not receiving another experimental treatment for glioblastoma at the moment of inclusion.
- Able to take oral medications.
- No known allergy to substance
- Absolute neutrophil count ≥ 1,500/mcL and platelets ≥ 100,000/mcL
Exclusion Criteria:
General
- Other likely diagnosis than glioblastoma based on MRI.
- Pregnant and/or breastfeeding.
- Women of childbearing potential who do not have a negative pregnancy test (not older than 14 days) before inclusion.
- History of active liver disease, including chronic active hepatitis, viral hepatitis (hepatitis B, C and CMV), cholestatic jaundice of any etiology or toxic hepatitis or inadequate hepatic function, defined as baseline ASAT and ALAT > 1.5 X upper institutional limit and/or bilirubin > 1.5 X upper institutional limit.
- Suspected significant raised intracranial pressure or other indication for emergent surgery
- Unfit for participation for any other reason judged by the including physician.
Specific additional exclusions criteria for disulfiram
- History of uncontrolled hypertension (i.e. systolic BP > 180 mmHg) and a diagnosis of congestive heart failure
- History of psychiatric conditions (e.g. depression, psychosis, schizophrenia) or dementia.
- History of Wilson's disease or family member with Wilson's disease (unless excluded as a carrier by genetic test).
- History of hemochromatosis or family member with hemochromatosis (unless excluded as a carrier by genetic test).
- Nickel hypersensitivity (disulfiram mobilize nickel causing a brief increase in nickel concentrations before excretion. The initial increase may lead to hepatitis and predisposed patients).7
- Need for metronidazole, warfarin and/or theophylline medication (the metabolism may be influenced by disulfiram).
- Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives (phenytoin, phenobarbital, chlordiazepoxide, imipramine, diazepam, isoniazid, metronidazole, warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram).
- Addiction to alcohol or drugs. Alcohol must be avoided.
- Serum/plasma copper and serum ceruloplasmin outside institutional limits. a. However increased levels are seen together with ongoing acute phase reaction as determined by elevated C-reactive protein (ceruloplasmin is elevated as part of the same process) it is possible to retest after normalization of C-reactive protein.
Specific additional exclusions criteria for metformin
- Diabetic patients or other patients where treating physician and/or anesthesiologist consider may have an increased risk for lactic acidosis per- and postoperatively
- Known renal failure, renal risk factors (including single kidney, donor kidney, polycystic kidneys) or estimated glomerular filtration rate below 80 ml/min.
- Congestive heart failure
- Scheduled diagnostic work-up where contrast medium containing iodine is indicated
- Concomitant use of NSAIDs (risk of renal injury)
- Risk of dehydration judged by the treating physician (e.g. when symptoms include vomiting)
- Alcohol must be avoidance during treatment (increased risk of lactic acidosis)
- Treatment with diuretics as they may increase risk of lactic acidosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Disulfiram
Disulfiram 200 mg twice daily and copper 2,5 mg once daily.
For bioavailability purpose only, treatment is withdrawn postoperatively
|
200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
|
Experimental: Metformin
Metformin 850 mg x 3 daily.
For bioavailability purpose only, treatment is withdrawn postoperatively
|
Metformin 850 mg x 3 taken preoperatively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailabilty disulfiram
Time Frame: At time of surgery
|
Concentration of disulifram-copper complex available in glioblastoma compared to blood
|
At time of surgery
|
Bioavailabilty of metformin
Time Frame: At time of surgery
|
Concentration of metformin available in glioblastoma compared to blood
|
At time of surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Asgeir S Jakola, MD, PhD, Sahlgrenska University Hospital, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Alcohol Deterrents
- Acetaldehyde Dehydrogenase Inhibitors
- Metformin
- Disulfiram
Other Study ID Numbers
- 1144-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Disulfiram
-
Psykiatrisk Center GentofteUnknown
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
University of RochesterNot yet recruitingAge-Related Macular Degeneration | Retinitis Pigmentosa | Retinal Dystrophies | Alcohol Use Disorder | Stargardt DiseaseUnited States
-
University of WashingtonRecruitingInherited Retinal Dystrophy Primarily Involving Sensory RetinaUnited States
-
Hadassah Medical OrganizationAugusta Hospital, BerlinCompletedNon-small Cell Lung CancerIsrael
-
Baylor College of MedicineCompletedCocaine AddictionUnited States
-
University of UtahCompleted
-
John P. FruehaufCompleted
-
Universidad de GuanajuatoLaboratorios Doctor MacíasEnrolling by invitation
-
First People's Hospital of HangzhouCollege of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute...Not yet recruitingChemotherapy;Advanced Gastric Cancer;Cisplatin;DisulfiramChina